Background: Oral squamous cell carcinoma (OSCC) is one of the most widespread cancer types that arise from different sites of oral cavity and has a 5-year survival rate. This study is aimed at investigating the human oxoguanine glycosylase 1 (hOGG1)-Ser326Cys and APE-Asp148Glu polymorphisms of DNA repair genes in OSCC. Materials and Methods: We investigated the hOGG1-Ser326Cys and APE-Asp148Glu polymorphisms of DNA repair genes in the oral cavity. Genotyping was conducted using polymerase chain reaction-restriction fragment length polymorphism analysis based on 132 patients who were diagnosed as having OSCC and 160 healthy subjects. Results: Individuals with the genotype hOGG1-Ser326Cys, Cys allele carriers, were found significantly more frequently in the patient group compared to the control group as increase in risk (p < 0.001). Furthermore, it was observed that there were significantly more individuals with the Ser allele in the control group (p < 0.001). Individuals with genotype APE-Asp148Glu were not statistically significant; however, they were still more in the control group and provided protection against the disease. Conclusion: Our findings showed that hOGG1-Ser326Cys Cys allele is statistically important and relevant with respect to the development of oral squamous cancer. In view of our results, further studies including expression levels are required in which hOGG1-Ser326Cys should be investigated as molecular biomarkers for the early prediction of squamous cell carcinoma.

1.
Cummings CW, Flint PW, Harker LA, et al: Otolaryngology-Head and Neck Surgery, ed 4. Philadelphia, Mosby, Inc., 2005, vol 2, pp 1578-1617.
2.
McDowell JD: An overview of epidemiology and common risk factors for oral squamous cell carcinoma. Otolaryngol Clin North Am 2006;39:277-294.
3.
Tanis T, Cincin ZB, Gokcen-Rohlig B, Bireller ES, Ulusan M, Tanyel CR, Cakmakoglu B: The role of components of the extracellular matrix and inflammation on oral squamous cell carcinoma metastasis. Arch Oral Biol 2014;59:1155-1163.
4.
Ries LAG, Melbert D, Krapcho M, et al: SEER Cancer Statistics Review 1975-2005. Bethesda, National Cancer Institute, 2008.
5.
Barnes L, Eveson JW, Reichart P, Sidransky D: World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumors. Lyon, IARC Press, 2005, pp 168-174.
6.
Goode EL, Ulrich CM, Potter JD: Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:1513-1530.
7.
Kastan MB: DNA damage responses: mechanisms and roles in human disease: 2007 G.H.A. Clowes Memorial Award Lecture. Mol Cancer Res 2008;6:517-524.
8.
Bao S, Wu Q, McLendon RE, et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760.
9.
Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA: DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008;8:193-204.
10.
Martin SA, Lord CJ, Ashworth A: DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev 2008;18:80-86.
11.
Hoeijmakers JH: Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366-374.
12.
Zhang Y, Chen SY, Hsu T, Santella RM: Immunohistochemical detection of malondialdehyde-DNA adducts in human oral mucosa cells. Carcinogenesis 2002;23:207-211.
13.
Santella RM, Gammon M, Terry M, et al: DNA adducts, DNA repair genotype/phenotype and cancer risk. Mutat Res 2005;592:29-35.
14.
Wood RD, Mitchell M, Sgouros J, Lindahl T: Human DNA repair genes. Science 2001;291:1284-1289.
15.
Attar R, Cacina C, Sozen S, Attar E, Agachan B: DNA repair genes in endometriosis. Genet Mol Res 2010;9:629-636.
16.
Ashton KA, Proietto A, Otton G, et al: Estrogen receptor polymorphisms and the risk of endometrial cancer. BJOG 2009;116:1053-1061.
17.
Krupa R, Sobczuk A, Popławski T, Wozniak K, Blasiak J: DNA damage and repair in endometrial cancer in correlation with the HOGG1 and RAD51 genes polymorphism. Mol Biol Rep 2011;38:1163-1170.
18.
Aktuglu MB, Ayer M, Bireller ES, et al: Investigation of DNA repair gene variants on myelodysplastic syndromes in a Turkish population. Med Oncol 2014;31:174.
19.
Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
20.
WHO Global Oral Health Programme: The World Oral Health Report 2003. Geneva, WHO, 2003.
21.
Kasai H: Analysis of a form of oxidative DNA damage, 8-hydroxy-2'-deoxyguanosine, as a marker of cellular oxidative stress during carcinogenesis. Mutat Res 1997;387:147-163.
22.
Elahi A, Zheng Z, Park J, Eyring K, McCaffrey T, Lazarus P: The human OGG1 DNA repair enzyme and its association with orolaryngeal cancer risk. Carcinogenesis 2002;23:1229-1234.
23.
Xing DY, Tan W, Song N, Lin DX: Ser326Cys polymorphism in hOGG1 gene and risk of esophageal cancer in a Chinese population. Int J Cancer 2001;95:140-143.
24.
Tsai CW, Tsai MH, Tsou YA, et al: The joint effect of smoking and hOGG1 genotype on oral cancer in Taiwan. Anticancer Res 2012;32:3799-3803.
25.
Farnebo L, Stjernström A, Fredrikson M, et al: DNA repair genes XPC, XPD, XRCC1, and XRCC3 are associated with risk and survival of squamous cell carcinoma of the head and neck. DNA Repair (Amst) 2015;31:64-72.
26.
Dos Santos Pereira J, Fontes FL, De Medeiros SR, De Almeida Freitas R, De Souza LB, Da Costa Miguel MC: Association of the XPD and XRCC3 gene polymorphisms with oral squamous cell carcinoma in a Northeastern Brazilian population: a pilot study. Arch Oral Biol 2015;64:19-23.
27.
Vascotto C, Cesaratto L, Zeef LA, et al: Genome-wide analysis and proteomic studies reveal APE1/Ref-1 multifunctional role in mammalian cells. Proteomics 2009;9:1058-1074.
28.
Shan JL, He HT, Li MX, et al: APE1 promotes antioxidant capacity by regulating Nrf-2 function through a redox-dependent mechanism. Free Radic Biol Med 2015;78:11-22.
29.
Li M, Wilson DM 3rd: Human apurinic/ apyrimidinic endonuclease 1. Antioxid Redox Signal 2014;20:678-707.
30.
Vogiatzi G, Tousoulis D, Stefanadis C: The role of oxidative stress in atherosclerosis. Hellenic J Cardiol 2009;50:402-409.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.